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Key Points
• BCR-ABL–specific CTLs may
be obtained by stimulation
with peptides derived from
BCR-ABL junctional region
and alternative splicing.
• T-cell therapy with BCR-
ABL–specific CTLs from
healthy donors or patients
mediates molecular or
hematologic CR in patients
with Ph1 ALL.
Although the emergence of bone marrow (BM)–resident p190BCR-ABL–specific
T lymphocytes has been correlated with hematologic and cytogenetic remissions in
patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph1
ALL) undergoing maintenance tyrosine-kinase inhibitor treatment, little is known about
the possibility of culturing these cells ex vivo and using them in T-cell therapy strategies.
We investigated the feasibilityof expanding/priming p190BCR-ABL–specificTcells invitro
by stimulation with dendritic cells pulsed with p190BCR-ABL peptides derived from the
BCR-ABL junctional regionandalternativesplicing, andof adoptively administering them
to patients with relapsed disease.We report on the feasibility of producing clinical-grade
BCR-ABL–specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity,
from Ph1 ALL patients and healthy donors. We treated 3 patients with Ph1 ALL with
autologous or allogeneic p190BCR-ABL–specific CTLs. No postinfusion toxicity was
observed, except for a grade II skin graft-versus-host disease in the patient treated for
hematologic relapse. All patients achieved a molecular or hematologic complete
remission (CR) after T-cell therapy, upon emergence of p190BCR-ABL–specific T cells in
the BM. Our results show that p190BCR-ABL–specific CTLs are capable of controlling treatment-refractory Ph1 ALL in vivo, and
support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph1 ALL. (Blood. 2017;129(5):582-586)
Introduction
Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph1
ALL) was formerly burdened by uniformly poor prognosis.1 Wide-
spread application of allogeneic hematopoietic stem cell (HSC) trans-
plantation (alloHSCT) and advent of targeted BCR-ABL–specific
tyrosine-kinase inhibitors (TKIs) have significantly improved complete
response rates and disease-free survival.1,2 Despite these therapeutic
advances, someunresolved issues remain, including thehighprevalence
in older patients,3 often ineligible for alloHSCT, and the extremely poor
prognosis of relapsed Ph1 ALL, particularly following alloHSCT.1,4
Prolonged hematologic and cytogenetic remissions have been
observed with imatinib mesylate (IM) alone, even in the presence
of persisting levels of minimal residual disease (MRD).5-7 Our group
was able to demonstrate that attainment of such clinical responses
directly correlated with the emergence of BCR-ABL–specific T cells
in the bone marrow (BM) and, to a lesser extent, in the peripheral
blood of nonallografted Ph1 ALL patients undergoing postremission
maintenance treatment with either IM or other second-generation
TKIs.8,9 These observations extended previous evidence of functional
leukemia-specific cellular immune responses developing in patients
receiving IM, and possibly acting in synergy with IM to reach disease
control,10,11 and represent the basis for a combined TKI and T-cell
therapy approach to Ph1 ALL in elderly patients, or in patients
relapsing after alloHSCT.
We report on the feasibility of inducing durableMRDclearance and
leukemia control, without additional toxicity, by transfer of donor-
derived or autologous cytotoxic T lymphocytes (CTLs) specific for the
BCR-ABL fusion product in patients receiving TKI treatment of
leukemia relapse after alloHSCT, or for molecular relapse in patients
ineligible for alloHSCT. In addition, we describe the immunological
parameters correlated with clinical response.
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Study design
Patient 1 was a 61-year-old man in second molecular recurrence after matched
unrelated donor (MUD) alloHSCT and unmanipulated donor lymphocyte
infusions (DLIs). Patient 2was a 30-year-oldman diagnosedwith Ph1ALLwith
hyperleukocytosis and central nervous system (CNS) involvement, in third
hematologic relapse (BM blast 66%, F317L mutation) after MUD-HSCT, DLI,
and rescue therapywithNilotinib. Patient 3was a 62-year-oldwoman diagnosed
withPh1ALLwithCNSinvolvement, showingpersistentmoleculardisease (last
MRDbefore T-cell therapy 0.1%BCR-ABL/ABL) after induction,maintenance
chemotherapy, and prolonged TKI treatment. Shewas not eligible for alloHSCT
due to comorbidities. Details on patients’ clinical histories are reported in
supplemental Methods (available on the BloodWeb site).
Methods for p190BCR-ABL–specific CTL preparation and testing are









































































































































Figure 1. Characteristics of the p190BCR-ABL–specific T cells used in the 3 patients. (A) T-cell expansion of p190BCR-ABL–specific T-cell lines achieved over a 40-day period
based on cell counting using trypan blue exclusion (green square, patient 1; blue circle, patient 2; red triangle, patient 3). (B) Phenotype of p190BCR-ABL–specific T-cell lines, reported
as the percentage of positive cells (green square, patient 1; blue circle, patient 2; red triangle, patient 3). (C) Response, measured as IFNg production in a enzyme-linked immunospot
(ELISPOT) assay, to the different peptide pools used in the activation/expansion process. Mix1int indicates 9- and 10-mer peptides spanning the internal p190 breakpoint region;
Mix1est, 9- and 10-mer peptides spanning the external p190 breakpoint region; Mix3, 9-mer peptides derived from the alternative BCR-ABL splice variants. (D) Cytotoxic activity of
T-cell lines, measured as the percentage of specific lysis at a effector-to-target (E:T) ratio of 5:1, against autologous phytohemagglutinin (PHA) blasts pulsed with p190BCR-ABL
peptides (BCR-ABL-PHA targets, cytotoxicity measured at 5 hours and 12 hours, calculated after subtraction of background, consisting of cytotoxicity against autologous PHA blasts
pulsed with irrelevant peptides), P815 cell line, nonpulsed PHA blasts from patients 1 and 2 (allo-PHA), nonpulsed autologous PHA blasts (auto-PHA) (red column, patient 1; blue
column, patient 2; green column, patient 3). (E) Cytotoxicity profile of p190BCR-ABL–specific CTLs obtained from patient 2. The figure reports the percentage of specific lysis against
patient ALL blasts (solid line and triangle), autologous PHA blasts pulsed with p190BCR-ABL peptides (dashed line and solid circle), P815 cell line (dotted line and solid squares),
nonpulsed PHA blasts of the patient (dashed-dotted line and empty circles). The mean percentage of lysis of duplicate wells for 5 different E:T ratios is shown. SFU, spot-forming unit.
















ILIA user on 04 February 2021




































































































































































I˚ II˚ III˚ IV˚ V˚ VI˚ IX˚ XII˚








Month from initiation of CTL therapy





















95% 85% 60% 40% 45% 85% 95% 100% 100%
























































































-2 -1 +1 +2 +3 +4 +5 +6 +7


















































































Figure 2. Clinical and immunological responses to
p190BCR-ABL–specific CTL infusion in 3 patients
with molecular or hematological relapse of Ph1
ALL. Longitudinal data tracking MRD kinetics (left
y-axis) and frequency of IFNg-, interleukin 2 (IL-2)-, and
tumor necrosis factor a (TNFa)-producing, p190BCR-
ABL–specific, CD81 and CD41 T cells in the BM of
patients, measured by flow cytometry and reported
as the percentage of positive cells (right y-axis) are
summarized in a single time-course graph for each
patient. For each cytokine-producing T-cell subset,
memory profiles are depicted over the related time
points, defined as following: CD62L2 CD45RA2 (effector
memory [EM]), CD62L1CD45RA2 (central memory
[CM]). On each patient’s graph, data on the percentage
of donor chimerism, TKI treatment, and cell therapy
(unmanipulated DLI; p190BCR-ABL–specific CTLs)
timing and dose are also reported.
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stimulation procedure has been previously reported.8 BCR-ABL–specific
treatment was administered on a compassionate basis according to bioethical
committee approval.
MRD values were measured sequentially on BM mononuclear cell (MC)
samples at baseline, and after each CTL infusion, by means of a previously
described reverse transcriptase–polymerase chain reaction quantification of
BCR-ABL transcripts.12 Immunological responses were evaluated sequentially
by flow cytometry (supplemental Methods).8,13
Results and discussion
BCR-ABL–specific CTLs were expanded from peripheral blood MCs
collected from the patient (case 3) or from HSC donors (cases 1-2)
(Figure 1A). CTL lines were polyclonal (supplemental Figure 1) and
included both CD31CD81 and CD31CD41 T cells (Figure 1B). Each
CTL line produced interferon g (IFNg) in response to at least 1 BCR-
ABLpeptidepool (Figure1C), and recognizedautologous targets pulsed
with BCR-ABL peptides and/or patient leukemia blasts (Figure 1D-E).
Cytotoxic activity was likelymediated by both CD81 and CD41T cells
because we observed lysis in both 5-hour and 12-hour assays, the latter
being HLA class II–restricted (supplemental Figure 2). Regarding
specific activity against BCR-ABL peptides, we observed a broad
response to the different peptide pools; of note, all CTLs recognized
mix3 peptides, which included epitopes derived from products of
BCR-ABL alternative splicing, confirming data on the suitability of
these proteins as leukemia-specific antigens capable of eliciting an
effective tumor-specific CTL response in vitro and also in vivo.14 As
previously reported,15,16 by stimulating with dendritic cells pulsed with
BCR-ABL peptides that included long peptides along with 9-mer
epitopes, and using homeostatic cytokines in the culture process,17 we
were able to prime leukemia-specific responses also in healthy donors.
Cells were administered in a dose-escalating manner on a
monthly schedule. The 3 patients received a mean of 10 monthly
infusions (range, 6-13). No immediate infusion-related adverse
events were observed, and no grade 2-4 toxicities, including
development of cytokine release syndrome, attributable to the
T-cell infusions were recorded during follow-up. Patient 2, treated
for hematologic relapse after alloHSCT, showed grade II skin graft-
versus-host disease after administration of dose-level 2, success-
fully treated with topic steroids.
Molecular or hematologic complete remission (MCR or HCR) was
obtained in all patients, associated with emergence of p190BCR-
ABL–specific T-cells (Figure 2). Patient 1, who had detectable BCR-
ABL transcripts in theBMprior to donorCTL treatment, achievedMCR
after 4 weeks from the first CTL dose. He was maintained inMCRwith
monthly T-cell infusions, associated with IM treatment, for 12 months.
After T-cell therapy discontinuation, he persists in MCR at 57-month
follow-up (Figure 2A). Patient 3, who had persistent molecular disease
and was ineligible for an alloHSCT, was treated with autologous
p190BCR-ABL–specific CTLs. She achieved MCR at month 16 from
cell therapy initiation (Figure2C). In thepatientwithhematologic relapse
(no. 2), we obtained HCR after 6 monthly p190BCR-ABL–specific CTL
infusions at lower doses (0.1-0.53 106 T cell/kg), in combination with
ponatinib treatment. Of note, in this last patient, the sole administration
of p190BCR-ABL–specific CTLs, before the introduction of ponatinib,
reduced BM blasts from 66% to 25%. Leukemia-specific T-cell
responses were undetectable in the BM prior to CTL administration in
all 3 patients. Progressive emergence of BM-resident, polyfunctional
(cases 1, 3), or IFNg-secreting (case 2) p190BCR-ABL–specific CD41
and CD81 T cells was associated with clearance of residual disease
(Figure 2). Parallel epitope spreading to WT-1-antigen was observed in
the patients’ BM (supplemental Figure 3).
Despite concerns on deleterious effects of TKIs on immune
effectors, experimental and clinical evidence obtained in patients
on long-term imatinib treatment suggests that the immune system
is functional, and may be harnessed toward antitumor surveil-
lance.18 After underscoring the role of p190BCR-ABL–specific
T cells, emerging during TKI treatment, in controlling Ph1 ALL,8
we show the feasibility of expanding/priming these T cells from
patients and HSCT donors, and demonstrate their excellent safety
profile and in vivo antileukemic activity, in combination with TKI
therapy.
In the last 5 years, impressive results have been obtained in the
control of relapsed/refractory ALL by administration of T lympho-
cytes genetically modified to express chimeric antigen receptors
(CARs) targeting B-cell–associated antigens.19-22 The increase in
CAR–T-cell clinical efficacy, however, has been paralleled by the
potential to induce severe adverse events, such as cytokine release
syndrome, and on-target off-tumor toxicities.19,21,23 In this regard,
BCR-ABL–specific CTLs may represent a valuable immunotherapeu-
tic option for patients not amenable to or experiencing severe adverse
events after CAR–T-cell infusion, or for patients with persistent levels
of MRD during TKI maintenance treatment after HSCT.
Clinical trials using immune checkpoint inhibitors (ICIs) have
shown enhancement of naturally occurring T-cell immunity against
cancers, with promising therapeutic results.24 In perspective,
combination treatments with ICIs or the bispecific T-cell antibody
blinatumomab25 could allow the prevention of T-cell anergy and
exhaustion after p190BCR-ABL–specific CTL infusions, thus
improving persistence of antileukemia CTLs and restoring a
durable immune surveillance against Ph1 ALL. At the same time,
leukemia-specific T cells mediating tumor lysis may expose
neoantigens, further potentiating the activity of ICIs.
Acknowledgments
This work was supported by grants from the Ministero della Salute
(Ricerca Finalizzata, GR-2010-2313609 [L.P.]; RF-2009-1548666
[P.C.]), the Associazione Italiana per la Ricerca sul Cancro (AIRC),
Milan, Italy (IG 14797-2013) (M.L.), AIRC 53 1000 (MCO1007)
(R.F.), and the Associazione Italiana Lotta alle Leucemie, Linfoma
eMieloma–Sezione ‘LucianoPavarotti’–Modena-ONLUS (L.P. and
F.F.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico
PoliclinicoSanMatteo (RicercaCorrente08069113 [P.C.]; 08045801/
10 and 08045801/11 [M.Z.]).
Authorship
Contribution: P.C., S.B., G.R., P. Barozzi, M.L., and L.P. conceived
and designed the study, analyzed results, and wrote the manuscript;
S.B., I.G., A.G., G.Q., L.R., I.L., D.V., and A.P., produced and
controlled CTL lines, processed samples, and executed experiments;
F.F., M.M., P. Bresciani, A. Cuoghi, A.P., and E.C., provided clinical
care, collected patient data, and commented on the manuscript; and
R.M., A. Cuneo, L.I., T.T., F.N., R.F., and M.Z. supervised the
study and critically revised the manuscript.
Conflict-of-interest disclosure: The authors declare no competing
financial interests.
















ILIA user on 04 February 2021
ORCID profiles: P.C., 0000-0001-5964-0553; S.B., 0000-0003-
2377-815X; P. Barozzi, 0000-0002-8936-1114; M.Z., 0000-0002-
8818-1744;M.L., 0000-0002-0373-1154; L.P., 0000-0002-2738-6105.
Correspondence: Patrizia Comoli, Oncoematologia Pediatrica,
Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19,
27100 Pavia, Italy; e-mail: pcomoli@smatteo.pv.it.
References
1. Fielding AK. How I treat Philadelphia
chromosome-positive acute lymphoblastic
leukemia. Blood. 2010;116(18):3409-3417.
2. Thomas DA, Faderl S, Cortes J, et al. Treatment
of Philadelphia chromosome-positive acute
lymphocytic leukemia with hyper-CVAD and
imatinib mesylate. Blood. 2004;103(12):
4396-4407.
3. Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-
biological features of 5202 patients with acute
lymphoblastic leukemia enrolled in the Italian
AIEOP and GIMEMA protocols and stratified in
age cohorts. Haematologica. 2013;98(11):
1702-1710.
4. Oriol A, Vives S, Hernández-Rivas JM, et al;
Programa Espa~nol de Tratamiento en
Hematologia Group. Outcome after relapse of
acute lymphoblastic leukemia in adult patients
included in four consecutive risk-adapted trials by
the PETHEMA Study Group. Haematologica.
2010;95(4):589-596.
5. Potenza L, Luppi M, Riva G, Marasca R, Martinelli
S, Torelli G. Efficacy of imatinib mesylate as
maintenance therapy in adults with acute
lymphoblastic leukemia in first complete
remission. Haematologica. 2005;90(9):
1275-1277.
6. Vignetti M, Fazi P, Cimino G, et al. Imatinib
plus steroids induces complete remissions and
prolonged survival in elderly Philadelphia
chromosome-positive patients with acute
lymphoblastic leukemia without additional
chemotherapy: results of the Gruppo Italiano
Malattie Ematologiche dell’Adulto (GIMEMA)
LAL0201-B protocol. Blood. 2007;109(9):
3676-3678.
7. Chiaretti S, Vitale A, Vignetti M, et al. A sequential
approach with imatinib, chemotherapy and
transplant for adult Ph1 acute lymphoblastic
leukemia: final results of the GIMEMA LAL 0904
study. Haematologica. 2016;101(12):1544-1552.
8. Riva G, Luppi M, Barozzi P, et al. Emergence of
BCR-ABL-specific cytotoxic T cells in the bone
marrow of patients with Ph1 acute lymphoblastic
leukemia during long-term imatinib mesylate
treatment. Blood. 2010;115(8):1512-1518.
9. Riva G, Luppi M, Quadrelli C, et al. BCR-ABL-
specific cytotoxic T cells in the bone marrow of
patients with Ph(1) acute lymphoblastic leukemia
during second-generation tyrosine-kinase inhibitor
therapy. Blood Cancer J. 2011;1(7):e30.
10. Chen CI, Maecker HT, Lee PP. Development and
dynamics of robust T-cell responses to CML
under imatinib treatment. Blood. 2008;111(11):
5342-5349.
11. Bocchia M, Gentili S, Abruzzese E, et al. Effect
of a p210 multipeptide vaccine associated with
imatinib or interferon in patients with chronic
myeloid leukaemia and persistent residual
disease: a multicentre observational trial. Lancet.
2005;365(9460):657-662.
12. Scheuring UJ, Pfeifer H, Wassmann B, et al. Early
minimal residual disease (MRD) analysis during
treatment of Philadelphia chromosome/Bcr-Abl-
positive acute lymphoblastic leukemia with the
Abl-tyrosine kinase inhibitor imatinib (STI571).
Blood. 2003;101(1):85-90.
13. Comoli P, Pedrazzoli P, Maccario R, et al. Cell
therapy of stage IV nasopharyngeal carcinoma
with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes. J Clin Oncol. 2005;
23(35):8942-8949.
14. Volpe G, Cignetti A, Panuzzo C, et al. Alternative
BCR/ABL splice variants in Philadelphia
chromosome-positive leukemias result in novel
tumor-specific fusion proteins that may represent
potential targets for immunotherapy approaches.
Cancer Res. 2007;67(11):5300-5307.
15. Bocchia M, Korontsvit T, Xu Q, et al. Specific
human cellular immunity to bcr-abl oncogene-
derived peptides. Blood. 1996;87(9):3587-3592.
16. Doubrovina E, Carpenter T, Pankov D,
Selvakumar A, Hasan A, O’Reilly RJ. Mapping of
novel peptides of WT-1 and presenting HLA
alleles that induce epitope-specific HLA-restricted
T cells with cytotoxic activity against WT-1(1)
leukemias. Blood. 2012;120(8):1633-1646.
17. Montagna D, Maccario R, Locatelli F, et al.
Ex vivo priming for long-term maintenance of
antileukemia human cytotoxic T cells suggests a
general procedure for adoptive immunotherapy.
Blood. 2001;98(12):3359-3366.
18. Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M,
Kroemer G. Immunological off-target effects of
imatinib. Nat Rev Clin Oncol. 2016;13(7):431-446.
19. Brentjens RJ, Rivière I, Park JH, et al. Safety and
persistence of adoptively transferred autologous
CD19-targeted T cells in patients with relapsed or
chemotherapy refractory B-cell leukemias. Blood.
2011;118(18):4817-4828.
20. Cruz CR, Micklethwaite KP, Savoldo B, et al.
Infusion of donor-derived CD19-redirected virus-
specific T cells for B-cell malignancies relapsed
after allogeneic stem cell transplant: a phase 1
study. Blood. 2013;122(17):2965-2973.
21. Maude SL, Teachey DT, Porter DL, Grupp SA.
CD19-targeted chimeric antigen receptor T-cell
therapy for acute lymphoblastic leukemia. Blood.
2015;125(26):4017-4023.
22. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-
T cells of defined CD41:CD81 composition in
adult B cell ALL patients. J Clin Invest. 2016;
126(6):2123-2138.
23. Morgan RA, Yang JC, Kitano M, Dudley ME,
Laurencot CM, Rosenberg SA. Case report of a
serious adverse event following the administration
of T cells transduced with a chimeric antigen
receptor recognizing ERBB2. Mol Ther. 2010;
18(4):843-851.
24. Armand P. Immune checkpoint blockade in
hematologic malignancies. Blood. 2015;125(22):
3393-3400.
25. Topp MS, Kufer P, Gökbuget N, et al. Targeted
therapy with the T-cell-engaging antibody
blinatumomab of chemotherapy-refractory
minimal residual disease in B-lineage acute
lymphoblastic leukemia patients results in high
response rate and prolonged leukemia-free
survival. J Clin Oncol. 2011;29(18):2493-2498.
















ILIA user on 04 February 2021
